Preface
There is no high-quality human evidence to support the use of TB-500 for any longevity, regenerative, anti-ageing or performance indication, and there is no regulatory approval for it in the UK, EU or US. Human data are limited to a single Phase I safety/pharmacokinetic study — and even that studied full-length recombinant thymosin β4 (Tβ4), not TB-500 itself.[1][2] All longevity use is experimental / expert-opinion at best, mechanistic-plausibility only, and is complicated by a theoretical oncological safety signal and a WADA sport prohibition.[3][4] On current evidence the recommendation is only in research / recommend against routine clinical use.
1. Scope
– Covered: TB-500 (a synthetic acetylated 7–amino-acid peptide, Ac-LKKTETQ, corresponding to residues 17–23 of thymosin β4) and, where relevant for extrapolation, full-length thymosin β4 (Tβ4). Focus is on adult longevity/preventive practice in a private UK clinic operating alongside NHS primary and secondary care.[3][1]
– Not covered: Approved Tβ4 ophthalmic formulations for neurotrophic keratopathy (a distinct licensed-trial context); other regenerative peptides (BPC-157, GHK-Cu, CJC-1295/ipamorelin) except by comparison; paediatric use.[3]
– Key caveat throughout: TB-500 is not identical to Tβ4 or to recombinant human Tβ4 used in trials; efficacy and safety data from Tβ4 must not be uncritically extrapolated to TB-500.[1]
2. Background and pathophysiology
– Biological rationale (mechanistic plausibility only): Tβ4 is an endogenous G-actin–sequestering peptide released by platelets and immune cells after injury. Distinct domains mediate distinct functions: residues 1–4 are anti-inflammatory, 1–15 anti-apoptotic/cytoprotective, and 17–23 (the TB-500 sequence) drive actin binding, cell migration, angiogenesis and wound healing.[5][3]
– Ageing relevance: Proposed mechanisms of interest are modulation of chronic low-grade inflammation (“inflammaging”), promotion of cell migration/stem-cell mobilisation, and VEGF-mediated angiogenesis in aged, poorly-healing tissue. These are hypotheses, not demonstrated clinical anti-ageing effects.[1]
– Robust human mechanistic evidence: None specific to TB-500. Human mechanistic data exist only for Tβ4 in wound-healing and cardiac contexts.[6][7]
– Preclinical subsection (animal/in-vitro — low weight): In rodents, Tβ4 accelerates dermal wound healing (diabetic, steroid-treated, aged mice), reduces scarring, acts as a chemoattractant for muscle stem cells and increases regenerating fibres — though not muscle strength — and reactivates an “embryonic” epicardial regenerative programme after cardiac injury. These findings are hypothesis-generating only and have not translated into validated human longevity outcomes.[3][7][8]
3. Evidence base and grading
– Study types available: No RCTs, meta-analyses or prospective cohorts of TB-500 for any longevity outcome. For Tβ4: Phase I safety trials, two Phase 2 dermal-ulcer trials, and a myocardial-infarction trial. Contemporary appraisals are narrative reviews.[3][7][2][4][1]
– Clinical outcomes studied: Safety/PK (Tβ4); dermal ulcer healing time (Tβ4); MI infarct size (Tβ4, mixed results). No mortality, morbidity, frailty, functional-status or validated ageing-biomarker endpoints for TB-500.[3][2][4]
GRADE-style certainty by outcome:
| Outcome | Evidence | Certainty | Strength of recommendation |
|---|---|---|---|
| Longevity / healthspan / mortality (TB-500) | No human studies | Very low (no data; indirect from Tβ4/animal) | Only in research / Recommend against [1], [4] |
| Musculoskeletal repair / athletic performance (TB-500) | Preclinical only; no efficacy signal in humans | Very low | Recommend against (also WADA-banned) [3], [4] |
| Dermal/tissue repair (Tβ4, not TB-500) | 2 Phase 2 ulcer trials (accelerated healing in those who healed) | Low (indirectness — Tβ4≠TB-500; small) | Only in research [7] |
| Short-term safety/tolerability (Tβ4, IV) | 1 first-in-human RCT (n=84 total, single+multiple dose) | Low–Moderate for Tβ4; Very low for TB-500 | Insufficient to establish TB-500 safety [1], [2] |
– Limitations across the base: high risk of bias/indirectness (wrong molecule, wrong population, surrogate endpoints), small samples, wide imprecision, and probable publication bias in a peptide field driven by commercial/social-media demand. No surrogate-to-hard-outcome linkage has been validated.[3][4]
4. Patient selection and indications
– Who might benefit: On current evidence, no patient group has a demonstrated benefit-risk profile favouring TB-500 for longevity indications. It should not be offered as routine care.[3][4]
– If considered at all (research context only): would require a clearly defined protocol, a specific regenerative endpoint, and exclusion of the high-risk groups below.
– Exclusion / high-risk groups: current or prior malignancy, strong family cancer history, or undiagnosed masses — because Tβ4 is overexpressed in and correlates with progression of colorectal, pancreatic, breast and lung cancers and promotes epithelial–mesenchymal transition and tumour angiogenesis (causality with exogenous peptide unproven, but a genuine theoretical hazard, especially long-term). Also exclude competitive athletes (WADA-prohibited).[3][4]
– Regulatory/ethical status (UK): Off-label is not applicable — TB-500 has no marketing authorisation; it is an unlicensed, unapproved “grey-market” compound with no MHRA/EMA/FDA approval and no pharmaceutical-grade quality assurance. Any use should be only within a research/clinical-trial framework with formal ethics approval; provision as private “adjunctive care” carries significant regulatory, product-quality and medicolegal risk.[3][4]
5. Assessment and baseline work-up
Because use should be confined to research, the following applies to a trial-governed setting:
– History/examination: full oncological history and red-flag screen; medication and supplement reconciliation; documentation of the specific regenerative complaint.
– Baseline investigations (expert consensus, not validated for TB-500): FBC, renal and liver function, HbA1c/lipids, and age/sex-appropriate cancer screening up to date. There is no validated biomarker to guide TB-500 dosing or monitoring.[1]
– Risk stratification: highest harm concern is occult malignancy; stratify primarily by cancer risk. No tool validates benefit prediction.
– Baseline documentation: informed-consent record explicitly stating unlicensed status, absence of efficacy data, and theoretical cancer risk; baseline photographs/functional measures if a regenerative endpoint is being studied.
6. Dosing regimens and practical implementation
– No evidence-based human dosing regimen exists for TB-500. Doses circulating in non-clinical/online sources are not derived from controlled human data and cannot be endorsed. Mayfield et al. explicitly note indications, dosing, frequency and duration “remain unknown”.[4]
– The only controlled human dosing data are for recombinant Tβ4 (NL005), not TB-500: single IV doses 0.05–25 μg/kg and multiple dosing 0.5–5.0 μg/kg once daily for 10 days, dose-proportional PK with no accumulation — a safety/PK study, not an efficacy or longevity regimen.[2]
– Robust-data regimens: none. All regimens are extrapolated from early-phase or preclinical data and require caution / should not be used outside research.[1][4]
7. Monitoring, safety and follow-up
– Short-term safety (Tβ4): Phase I trials report mild-to-moderate, placebo-comparable adverse events, no dose-limiting toxicity and no serious adverse events over ≤28 days. This does not establish TB-500 safety, and no long-term human safety data exist for either peptide.[3][2][1]
– Principal serious concern: theoretical promotion or acceleration of occult malignancy through pro-angiogenic/EMT mechanisms, particularly with prolonged use.[3]
– Monitoring (expert consensus only, unvalidated): clinical review for new masses, unexplained weight loss or bleeding; maintain up-to-date national cancer screening; there is no established lab or imaging monitoring protocol and no validated ageing biomarker to track.[1]
– Suggested intervals (pragmatic): clinical review at short (weeks), medium (3 months) and long term; stop immediately and refer via suspected-cancer pathways for any red-flag finding.
– Interactions: not characterised in humans. Product-contamination and dosing-inaccuracy risks are substantial given grey-market sourcing.[3][4]
– Special populations: avoid in pregnancy and breastfeeding (no data); no renal/hepatic dosing data; caution in frailty/extremes of age given absent evidence.
8. Contraindications and cautions
– Absolute (on precautionary grounds): active or recent malignancy; pregnancy/breastfeeding; competitive athletes subject to anti-doping testing (WADA-prohibited).[3][4]
– Relative / specialist input required: personal or strong family history of cancer; undiagnosed masses or unexplained symptoms; use of any unlicensed/grey-market product without quality assurance.
– Harm likely to outweigh benefit: essentially all routine longevity use at present, given zero demonstrated benefit against a real theoretical harm.[3][4]
9. Practical management scenarios
Scenario A — Middle-aged patient with multiple cardiometabolic risk factors requesting TB-500 for “healthspan”:
– Recommendation: Avoid / offer evidence-based alternatives (Strong). No data support cardiometabolic longevity benefit.
– Assess and treat conventionally (lipids, BP, glycaemia, weight, exercise); use shared decision-making to explain the absence of efficacy data and the theoretical cancer risk; do not initiate; redirect to interventions with mortality/morbidity evidence.
Scenario B — Older, frail patient with multimorbidity:
– Recommendation: Avoid (Strong). Highest cumulative cancer and polypharmacy/interaction risk, no functional or frailty outcome data.[3][4]
– Optimise conventional frailty management (resistance exercise, nutrition, medication review); document rationale for not offering TB-500.
Scenario C — Patient with a healing wound/injury already under specialist care, asking for TB-500 as an adjunct:
– Recommendation: Restrict to research only (Conditional against outside trials). Tβ4 (not TB-500) has only low-certainty Phase 2 signals in chronic ulcers.[7]
– Defer to the treating specialist and standard wound/injury care; if the patient wishes to pursue the peptide, direct to a registered clinical trial and obtain explicit informed consent about unlicensed status.
For all scenarios: escalate/refer for any new or suspicious symptom; stop any peptide immediately if red flags emerge.
10. Research gaps and future directions
– Molecule-specific data: almost all human data concern Tβ4, not TB-500; dedicated TB-500 pharmacology, safety and efficacy studies are needed.[1]
– Priority questions: validated longevity/functional endpoints (not surrogates); long-term oncological safety; optimal dose/route/duration; product quality standards.[4][1]
– Recommended posture: confine any TB-500 (and by extension Tβ4-for-longevity) use to well-designed, ethically approved clinical trials or registries until controlled human efficacy and long-term safety data exist.[3][1]
References
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Mavrych V, Shypilova I, Bolgova O. Frontiers in Aging. 2026;7:1790247. doi:10.3389/fragi.2026.1790247.
- A First-in-Human, Randomized, Double-Blind, Single- And Multiple-Dose, Phase I Study of Recombinant Human Thymosin Β4 in Healthy Chinese Volunteers. Wang X, Liu L, Qi L, et al. Journal of Cellular and Molecular Medicine. 2021;25(17):8222-8228. doi:10.1111/jcmm.16693.
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Mendias CL, Awan TM. Sports Medicine (Auckland, N.Z.). 2026;56(8):1921-1935. doi:10.1007/s40279-026-02437-0.
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Mayfield CK, Bolia IK, Feingold CL, et al. The American Journal of Sports Medicine. 2026;54(1):223-229. doi:10.1177/03635465251357593.
- An Investigation on the Therapeutic Effect of Thymosin β4 and Its Expression Levels in Streptozotocin‐Induced Diabetic Mice. Cho KS, Kim DJ, Shim B, et al. BioMed Research International. 2018;2018:3421568. doi:10.1155/2018/3421568.
- Advances in the Basic and Clinical Applications of Thymosin Β4. Goldstein AL, Kleinman HK. Expert Opinion on Biological Therapy. 2015;15 Suppl 1:S139-45. doi:10.1517/14712598.2015.1011617.
- The Regenerative Peptide Thymosin Β4 Accelerates the Rate of Dermal Healing in Preclinical Animal Models and in Patients. Treadwell T, Kleinman HK, Crockford D, et al. Annals of the New York Academy of Sciences. 2012;1270:37-44. doi:10.1111/j.1749-6632.2012.06717.x.
- Thymosin Beta-4 Denotes New Directions Towards Developing Prosperous Anti-Aging Regenerative Therapies. Bock-Marquette I, Maar K, Maar S, et al. International Immunopharmacology. 2023;116:109741. doi:10.1016/j.intimp.2023.109741.
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Mendias CL, Awan TM. Sports Medicine (Auckland, N.Z.). 2026;56(8):1921-1935. doi:10.1007/s40279-026-02437-0.
- Therapeutic Peptides in Gerontology: Mechanisms and Applications for Healthy Aging. Mavrych V, Shypilova I, Bolgova O. Frontiers in Aging. 2026;7:1790247. doi:10.3389/fragi.2026.1790247.